104 related articles for article (PubMed ID: 38951849)
1. The vacated space of volume/price of the drugs centralized procurement with quantity in secondary and above public hospitals of China.
Wang J; Zhang S; Wang C; Li J; Wang R; Zhu L
BMC Health Serv Res; 2024 Jun; 24(1):771. PubMed ID: 38951849
[TBL] [Abstract][Full Text] [Related]
2. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
Wang N; Yang Y; Xu L; Mao Z; Cui D
BMC Public Health; 2021 Oct; 21(1):1883. PubMed ID: 34663282
[TBL] [Abstract][Full Text] [Related]
3. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
[TBL] [Abstract][Full Text] [Related]
4. The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China.
Chen L; Yang Y; Luo M; Hu B; Yin S; Mao Z
Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33334027
[TBL] [Abstract][Full Text] [Related]
5. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
Zhao B; Wu J
Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
[TBL] [Abstract][Full Text] [Related]
6. Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series.
Long H; Yang Y; Geng X; Mao Z; Mao Z
Front Pharmacol; 2022; 13():944540. PubMed ID: 35910351
[No Abstract] [Full Text] [Related]
7. The change of drug utilization in China's public healthcare institutions under the "4 + 7" centralized drug procurement policy: Evidence from a natural experiment in China.
Lu J; Long H; Shen Y; Wang J; Geng X; Yang Y; Mao Z; Li J
Front Pharmacol; 2022; 13():923209. PubMed ID: 36081942
[No Abstract] [Full Text] [Related]
8. "4+7" city drug volume-based purchasing and using pilot program in China and its impact.
Tang M; He J; Chen M; Cong L; Xu Y; Yang Y; Hou Z; Song P; Jin C
Drug Discov Ther; 2019; 13(6):365-369. PubMed ID: 31956236
[TBL] [Abstract][Full Text] [Related]
9. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
Lan T; Guan L; Pang X; Li X; Yu Q
J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
[TBL] [Abstract][Full Text] [Related]
10. Does China's centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model.
Gu Y; Zhuang Q
Front Pharmacol; 2023; 14():1192423. PubMed ID: 37324496
[No Abstract] [Full Text] [Related]
11. The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China.
Yang Y; Hu R; Geng X; Mao L; Wen X; Wang Z; Hao S; Cui D; Mao Z
Int J Health Plann Manage; 2022 May; 37(3):1650-1662. PubMed ID: 35132676
[TBL] [Abstract][Full Text] [Related]
12. Analysis and discussion on the pharmaceutical centralized procurement implementation - a case study of a large provincial hospital in China.
Cao J; Ren Y; Zhao C; Wang L; Fang F
Front Pharmacol; 2024; 15():1379595. PubMed ID: 38887552
[TBL] [Abstract][Full Text] [Related]
13. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis.
Yang Y; Chen L; Ke X; Mao Z; Zheng B
BMC Health Serv Res; 2021 Jul; 21(1):668. PubMed ID: 34238290
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
15. Impact of China's National Centralized Drug Procurement Policy on pharmaceutical enterprises' financial performance: a quasi-natural experimental study.
Sun Z; Na X; Chu S
Front Public Health; 2023; 11():1227102. PubMed ID: 38026347
[TBL] [Abstract][Full Text] [Related]
16. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
[TBL] [Abstract][Full Text] [Related]
17. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
[TBL] [Abstract][Full Text] [Related]
18. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
19. The impacts of national centralized drug procurement policy on drug utilization of medical institutions: an empirical study in a county-level hospital in China.
Li H; Lin F; Wang R; Zhu C; Cao K; Chen Y; Fang G; Li J; Ding J; Li W
BMC Health Serv Res; 2024 Apr; 24(1):513. PubMed ID: 38658940
[TBL] [Abstract][Full Text] [Related]
20. Improving access to medicines and beyond: the national volume-based procurement policy in China.
Zhu Z; Wang Q; Sun Q; Lexchin J; Yang L
BMJ Glob Health; 2023 Jul; 8(7):. PubMed ID: 37463786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]